1. Medtech Insight
  2. >>Archive

Inverness buys POC (point-of-care) firm for $33m:

Inverness Medical Innovations has notched up its ninth acquisition of 2007, after buying point-of-care (POC) diagnostics distributor Bio-Stat Healthcare for $33.4m. Inverness will pay an earn-out of up to $14.6m based on Bio-Stat's 2007 financial results. Stockport, UK-based Bio-Stat, which recorded revenues of $29.5m in 2006, will provide Inverness with further presence in the European market after it purchased Promesan, an Italian POC test distributor in February (see Clinica No 1243, p 14). Inverness has also purchased Cholestech, Matritech, HemoSense, Biosite, Spectral Diagnostics, First Check Diagnostics and Med-Ox this year, as well as buying a 75% stake in Instant Technologies.

Inverness Medical Innovations has notched up its ninth acquisition of 2007, after buying point-of-care (POC) diagnostics distributor Bio-Stat Healthcare for $33.4m. Inverness will pay an earn-out of up to $14.6m based on Bio-Stat's 2007 financial results. Stockport, UK-based Bio-Stat, which recorded revenues of $29.5m in 2006, will provide Inverness with further presence in the European market after it purchased Promesan, an Italian POC test distributor in February (see Clinica No 1243, p 14). Inverness has also purchased Cholestech, Matritech, HemoSense, Biosite, Spectral Diagnostics, First Check Diagnostics and Med-Ox this year, as well as buying a 75% stake in Instant Technologies.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Execs On The Move: July 7–11, 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

EU Authorities Unite In Call For Urgent Overhaul Of Medtech Regulations

 
• By Amanda Maxwell

EU member states have issued a consensus statement on the urgent need to build momentum to tackle governance and centralization issues as part of much-needed reform of the EU medtech regulatory system.

‘Eyes – A Window Into The Heart’: Retinal AI Tool Predicts Future Risk Of Heart Attack And Stroke

 
• By Natasha Barrow

A deep-learning AI-based retinal image scanning tool can predict the risk of cardiovascular events over a 10-year period with 70% accuracy. The test is comparable to routine GP health checks, researchers from the University of Dundee have shown.